Drug Profile


Alternative Names: Artesunate-mefloquine; ASMQ FDC; Mefliam Plus; Mefloquine/artesunate

Latest Information Update: 22 May 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Drugs for Neglected Diseases Initiative Foundation
  • Developer Cipla; Drugs for Neglected Diseases Initiative Foundation; Oswaldo Cruz Foundation
  • Class Antimalarials; Artemisinins; Phytotherapies; Quinolines; Sesquiterpenes
  • Mechanism of Action Free radical stimulants; Sarcoplasmic reticulum calcium-transporting ATPase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Falciparum malaria

Most Recent Events

  • 19 May 2017 Launched for Falciparum malaria in Cameroon and Thailand (PO) before May 2017 (DNDi website, May 2017)
  • 19 May 2017 Artesunate/mefloquine is still pending registration for Falciparum malaria in Laos, Philippines, Papua New Guinea, Indonesia, Kenya, Ghana, Benin, Togo, Chad, Ivory Coast, Republic of Guinea, Senegal, Democratic Republic of Congo, Malawi, Congo, and Mali (PO) (DNDi website, May 2017)
  • 30 Mar 2015 Launched for Falciparum malaria in Malaysia, Myanmar, Vietnam, Cambodia, Niger, Burkina Faso and Tanzania (PO) by March 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top